Improved Cyclopropanation Activity of Histidine-Ligated Cytochrome P450 Enables the Enantioselective Formal Synthesis of Levomilnacipran
Engineering enzymes capable of modes of activation unprecedented in nature will increase the range of industrially important molecules that can be synthesized through biocatalysis. However, low activity for a new function is often a limitation in adopting enzymes for preparative‐scale synthesis, rea...
Saved in:
Published in | Angewandte Chemie International Edition Vol. 53; no. 26; pp. 6810 - 6813 |
---|---|
Main Authors | , , , , , |
Format | Journal Article |
Language | English |
Published |
Weinheim
WILEY-VCH Verlag
23.06.2014
WILEY‐VCH Verlag Wiley |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Engineering enzymes capable of modes of activation unprecedented in nature will increase the range of industrially important molecules that can be synthesized through biocatalysis. However, low activity for a new function is often a limitation in adopting enzymes for preparative‐scale synthesis, reaction with demanding substrates, or when a natural substrate is also present. By mutating the proximal ligand and other key active‐site residues of the cytochrome P450 enzyme from Bacillus megaterium (P450‐BM3), a highly active His‐ligated variant of P450‐BM3 that can be employed for the enantioselective synthesis of the levomilnacipran core was engineered. This enzyme, BM3‐Hstar, catalyzes the cyclopropanation of N,N‐diethyl‐2‐phenylacrylamide with an estimated initial rate of over 1000 turnovers per minute and can be used under aerobic conditions. Cyclopropanation activity is highly dependent on the electronic properties of the P450 proximal ligand, which can be used to tune this non‐natural enzyme activity.
Old cytochrome, new tricks: Mutation of the proximal Cys residue in the cytochrome P450 enzyme from Bacillus megaterium (P450‐BM3) leads to highly active, oxygen tolerant, and enantioselective catalysts for the cyclopropanation of N,N‐diethyl‐2‐phenylacrylamide. Directed evolution of a histidine‐ligated P450‐BM3 enabled the enantioselective formal synthesis of levomilnacipran. |
---|---|
Bibliography: | Gordon and Betty Moore Foundation - No. GBMF2809 National Institutes of Health - No. F32EB015846-01 ark:/67375/WNG-CJV45L03-G ArticleID:ANIE201402809 We thank Dr. S. Virgil and the Center for Catalysis and Chemical Synthesis (3CS) at Caltech for assistance with HPLC, Dr. J. McIntosh and Dr. T. Heel for helpful discussions, and R. Kitto for help during preparative-scale reactions. This work was supported by the Gordon and Betty Moore Foundation through Grant GBMF2809 to the Caltech Programmable Molecular Technology Initiative. Z.J.W. was supported by a Ruth L. Kirschstein Fellowship from the National Institutes of Health, award number F32EB015846-01. istex:ABCD36EE1BFCC9D943FE49C0A5EB3D7E05F1F513 These authors contributed equally to this work. We thank Dr. S. Virgil and the Center for Catalysis and Chemical Synthesis (3CS) at Caltech for assistance with HPLC, Dr. J. McIntosh and Dr. T. Heel for helpful discussions, and R. Kitto for help during preparative‐scale reactions. This work was supported by the Gordon and Betty Moore Foundation through Grant GBMF2809 to the Caltech Programmable Molecular Technology Initiative. Z.J.W. was supported by a Ruth L. Kirschstein Fellowship from the National Institutes of Health, award number F32EB015846‐01. NIH RePORTER Dr. Z. J. Wang and Dr. H. Renata contributed equally to this work. |
ISSN: | 1433-7851 1521-3773 |
DOI: | 10.1002/anie.201402809 |